-
Something wrong with this record ?
Non-Hodgkin lymphoma presenting with spinal cord compression: A population-based analysis of the NHL-BFM study group
A. Riquelme, J. Werner, M. Zimmermann, H. von Mersi, E. Kabíčková, F. Ceppi, J. Foerster, J. Finger, S. Müller, A. Attarbaschi, B. Burkhardt, W. Woessmann
Language English Country United States
Document type Journal Article
Grant support
Deutsche Kinderkrebsstiftung
PubMed
38961598
DOI
10.1002/pbc.31182
Knihovny.cz E-resources
- MeSH
- Child MeSH
- Spinal Cord Compression * etiology MeSH
- Humans MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Follow-Up Studies MeSH
- Lymphoma, Non-Hodgkin * complications pathology epidemiology MeSH
- Child, Preschool MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Spinal cord compression is a rare presentation of non-Hodgkin lymphoma (NHL) in children. We aimed to describe the prevalence, histological subtypes, clinical presentation, therapy, and outcome of those children in a population-based cohort. The chemotherapy regimen remained comparable over time. METHODS: We retrospectively identified all children and adolescents with paresis as initial manifestations of the NHL between January 1990 and December 2020 from the NHL-BFM database. Characteristics, therapy, and outcome data were gathered from the database and patient files. RESULTS: Fifty-seven of 4779 children (1.2%) presented with initial paresis due to spinal cord compression. The median age was 10.3 years (range, 3.1-18.0 years), and 33% were female. Initial symptoms were paresis/weakness (n = 50, 88%), back pain (n = 33, 58%), paresthesia (n = 23, 40%), and bladder dysfunction and/or constipation (n = 22, 39%), persisting for a median of 14 days before diagnosis. Subtype distribution was mature B-NHL (n = 41, 72%), precursor B-lymphoblastic lymphoma (LBL) (n = 12, 21%), anaplastic large cell lymphoma (ALCL) (n = 3, 5%), and T-LBL (n = 1, 2%). Initial emergency therapy included surgery (70%) and/or chemotherapy/steroids (63%). Five-year event-free survival and overall survival (80% ± 5% and 82% ± 5%, respectively) were comparable with all other NHL patients. Neurological symptoms persisted in approximately one-third of surviving patients at the last follow-up. CONCLUSION: 1.2% of pediatric NHL patients presented with paresis from spinal cord compression mainly due to B-cell lymphomas. Neurological sequelae were observed in one-third of surviving patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019123
- 003
- CZ-PrNML
- 005
- 20241024111552.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/pbc.31182 $2 doi
- 035 __
- $a (PubMed)38961598
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Riquelme, Amambay $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
- 245 10
- $a Non-Hodgkin lymphoma presenting with spinal cord compression: A population-based analysis of the NHL-BFM study group / $c A. Riquelme, J. Werner, M. Zimmermann, H. von Mersi, E. Kabíčková, F. Ceppi, J. Foerster, J. Finger, S. Müller, A. Attarbaschi, B. Burkhardt, W. Woessmann
- 520 9_
- $a BACKGROUND: Spinal cord compression is a rare presentation of non-Hodgkin lymphoma (NHL) in children. We aimed to describe the prevalence, histological subtypes, clinical presentation, therapy, and outcome of those children in a population-based cohort. The chemotherapy regimen remained comparable over time. METHODS: We retrospectively identified all children and adolescents with paresis as initial manifestations of the NHL between January 1990 and December 2020 from the NHL-BFM database. Characteristics, therapy, and outcome data were gathered from the database and patient files. RESULTS: Fifty-seven of 4779 children (1.2%) presented with initial paresis due to spinal cord compression. The median age was 10.3 years (range, 3.1-18.0 years), and 33% were female. Initial symptoms were paresis/weakness (n = 50, 88%), back pain (n = 33, 58%), paresthesia (n = 23, 40%), and bladder dysfunction and/or constipation (n = 22, 39%), persisting for a median of 14 days before diagnosis. Subtype distribution was mature B-NHL (n = 41, 72%), precursor B-lymphoblastic lymphoma (LBL) (n = 12, 21%), anaplastic large cell lymphoma (ALCL) (n = 3, 5%), and T-LBL (n = 1, 2%). Initial emergency therapy included surgery (70%) and/or chemotherapy/steroids (63%). Five-year event-free survival and overall survival (80% ± 5% and 82% ± 5%, respectively) were comparable with all other NHL patients. Neurological symptoms persisted in approximately one-third of surviving patients at the last follow-up. CONCLUSION: 1.2% of pediatric NHL patients presented with paresis from spinal cord compression mainly due to B-cell lymphomas. Neurological sequelae were observed in one-third of surviving patients.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a komprese míchy $x etiologie $7 D013117
- 650 12
- $a nehodgkinský lymfom $x komplikace $x patologie $x epidemiologie $7 D008228
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a následné studie $7 D005500
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Werner, Jana $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0009000263996960
- 700 1_
- $a Zimmermann, Martin $u Department of Pediatric Hematology and Oncology, Children's Hospital, Hannover Medical School, Hannover, Germany
- 700 1_
- $a von Mersi, Hannah $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Kabíčková, Edita $u Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Ceppi, Francesco $u Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
- 700 1_
- $a Foerster, Jan $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Finger, Jasmin $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Hospital Muenster, Muenster, Germany
- 700 1_
- $a Müller, Stephanie $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Hospital Muenster, Muenster, Germany
- 700 1_
- $a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria $u St. Anna Children's Cancer Research Institute, Vienna, Austria $1 https://orcid.org/0000000292856898
- 700 1_
- $a Burkhardt, Birgit $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Hospital Muenster, Muenster, Germany
- 700 1_
- $a Woessmann, Wilhelm $u Pediatric Hematology and Oncology and NHL-BFM Study Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
- 773 0_
- $w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 71, č. 9 (2024), s. e31182
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38961598 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111546 $b ABA008
- 999 __
- $a ok $b bmc $g 2201758 $s 1231096
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 71 $c 9 $d e31182 $e 20240703 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
- GRA __
- $p Deutsche Kinderkrebsstiftung
- LZP __
- $a Pubmed-20241015
